Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 3/2012

01-06-2012 | Original Paper

Lifetime costs of the top five cancers in Taiwan

Authors: Hui-Chu Lang, Shi-Liang Wu

Published in: The European Journal of Health Economics | Issue 3/2012

Login to get access

Abstract

The purpose of this study was to determine cancer-related medical care costs for long-term cancer care costs of breast, cervical, liver, lung, and colorectal cancer. Data were sourced from Taipei Veterans General Hospital cancer registry and claim data during 1999–2002. Besides, claimed data from National Health Insurance were used to match the comparison group. To estimate lifetime cost (10 years), the whole disease process was divided into initial, continuing, and terminal three phases. The expected lifetime cost of a specific cancer patient was estimated by incorporating the average phase-specific costs with the survival rate and mortality rate. The undiscounted average lifetime costs (10 years) for lung cancer, colorectal cancer, liver cancer, cervical cancer, and breast cancer were NT$448,371 (1USD≒NTD 33), NT$584,985, NT$351,222, NT$511,563, and NT$674,282 (in 2002 NTD), respectively. The aggregate lifetime cost of cancer is useful for health policymaking and clinical decision-making.
Literature
1.
Department of Health EY. Cancer registry annual report in Taiwan Area, 2006. Department of Health, Executive Yuan. Taipei (2009)
2.
Chen, C.J., You, S.L., Lin, L.H., Hsu, W.L., Yang, Y.W.: Cancer epidemiology and control in Taiwan: a brief review. Jpn. J. Clin. Oncol. 32(Suppl), S66–S81 (2002)PubMedCrossRef
3.
Chu, P.C., Hwang, J.S., Wang, J.D., Chang, Y.Y.: Estimation of the financial burden to the National Health Insurance for patients with major cancers in Taiwan. J. Formos. Med. Assoc. 107, 54–63 (2008)PubMedCrossRef
4.
Liu, C.N., Yang, M.C.: National health insurance expenditure for adult beneficiaries in Taiwan in their last year of life. J. Formos. Med. Assoc. 101(8), 552–559 (2002)PubMed
5.
White, E., Urban, N., Taylor, V.: Mammography utilization, public health impact, and cost-effectiveness in the United States. Annu. Rev. Public Health 14, 605–633 (1993)PubMedCrossRef
6.
Chen, Y.S., Wang, W.H., Chan, T., Sun, S.S., Kao, A.: A review of the cost-effectiveness of Tc-99 m sestamibi scintimammography in diagnosis of breast cancer in Taiwanese women with indeterminate mammographically dense breast. Surg. Oncol. 11(3), 151–155 (2002)PubMedCrossRef
7.
Selby, J.V., Friedman, G.D., Quesenberry Jr., C.P., Weiss, N.S.: A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 326(10), 653–657 (1992)PubMedCrossRef
8.
Chen, T.H., Yen, M.F., Lai, M.S., et al.: Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project. Cancer 86(7), 1116–1128 (1999)PubMedCrossRef
9.
Baker, M.S., Kessler, L.G., Urban, N., Smucker, R.C.: Estimating the treatment costs of breast and lung cancer. Med. Care 29(1), 40–49 (1991)PubMedCrossRef
10.
Lang, H.C., Wu, J.C., Yen, S.H., Lan, C.F., Wu, S.L.: The lifetime cost of hepatocellular carcinoma: a claims data analysis from a medical centre in Taiwan. Appl. Health Econ. Health Policy 6(1), 55–65 (2008)PubMedCrossRef
11.
Riley, G.F., Lubitz, J.D.: Longitudinal patterns of Medicare use by cause of death. Health Care Financ. Rev. 11(2), 1–12 (1989)PubMed
12.
Koroukian, S.M., Beaird, H., Madigan, E., Diaz, M.: End-of-life expenditures by Ohio Medicaid beneficiaries dying of cancer. Health Care Financ. Rev. 28(2), 65–80 (2006)PubMed
13.
Riley, G., Lubitz, J., Prihoda, R., Rabey, E.: The use and costs of Medicare services by cause of death. Inquiry 24(3), 233–244 (1987)PubMed
14.
Kardamanidis, K., Lim, K., Da Cunha, C., Taylor, L.K., Jorm, L.R.: Hospital costs of older people in New South Wales in the last year of life. Med. J. Aust. 187(7), 383–386 (2007)PubMed
15.
de Kok, I.M., Polder, J.J., Habbema, J.D., et al.: The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br. J. Cancer 100(8), 1240–1244 (2009)PubMedCrossRef
16.
Brown, M.L., Riley, G.F., Schussler, N., Etzioni, R.: Estimating health care costs related to cancer treatment from SEER-Medicare data. Med. Care 40(8 Suppl), IV-104–IV-117 (2002)
17.
Warren, J.L., Brown, M.L., Fay, M.P., Schussler, N., Potosky, A.L., Riley, G.F.: Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J. Clin. Oncol. 20(1), 307–316 (2002)PubMedCrossRef
18.
Kutikova, L., Bowman, L., Chang, S., Long, S.R., Obasaju, C., Crown, W.H.: The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50(2), 143–154 (2005)PubMedCrossRef
19.
Dedes, K.J., Szucs, T.D., Bodis, S., et al.: Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 22(7), 435–444 (2004)PubMedCrossRef
20.
Riley, G.F., Warren, J.L., Potosky, A.L., Klabunde, C.N., Harlan, L.C., Osswald, M.B.: Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans. Med. Care 46(10), 1108–1115 (2008)PubMedCrossRef
21.
Will, B.P., Berthelot, J.M., Le Petit, C., Tomiak, E.M., Verma, S., Evans, W.K.: Estimates of the lifetime costs of breast cancer treatment in Canada. Eur. J. Cancer 36(6), 724–735 (2000)PubMedCrossRef
22.
Riley, G.F., Potosky, A.L., Lubitz, J.D., Kessler, L.G.: Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med. Care 33(8), 828–841 (1995)PubMedCrossRef
23.
Riley, G.F., Potosky, A.L., Klabunde, C.N., Warren, J.L., Ballard-Barbash, R.: Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. JAMA 281(8), 720–726 (1999)PubMedCrossRef
24.
Riley, G.F., Potosky, A.L., Lubitz, J.D., Brown, M.L.: Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. Am. J. Public Health 84(10), 1598–1604 (1994)PubMedCrossRef
25.
Taplin, S.H., Barlow, W., Urban, N., et al.: Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J. Natl Cancer Inst. 87(6), 417–426 (1995)PubMedCrossRef
26.
Etzioni, R., Urban, N., Baker, M.: Estimating the costs attributable to a disease with application to ovarian cancer. J. Clin. Epidemiol. 49(1), 95–103 (1996)PubMedCrossRef
27.
Potosky, A.L., Riley, G.F., Lubitz, J.D., Mentnech, R.M., Kessler, L.G.: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med. Care 31(8), 732–748 (1993)PubMedCrossRef
28.
Ramsey, S.D., Berry, K., Etzioni, R.: Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am. J. Gastroenterol. 97(2), 440–445 (2002)PubMedCrossRef
29.
Brown, M.L., Riley, G.F., Potosky, A.L., Etzioni, R.D.: Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med. Care 37(12), 1249–1259 (1999)PubMedCrossRef
Metadata
Title
Lifetime costs of the top five cancers in Taiwan
Authors
Hui-Chu Lang
Shi-Liang Wu
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 3/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-011-0307-1

Other articles of this Issue 3/2012

The European Journal of Health Economics 3/2012 Go to the issue

Original Paper

Impact of healthcare reforms on out-of-pocket health expenditures in Turkey for public insurees

Original Paper

Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data

Original Paper

Formal and informal care for disabled elderly living in the community: an appraisal of French care composition and costs

Original Paper

I feel good! Gender differences and reporting heterogeneity in self-assessed health

Original Paper

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

Original Paper

The demand for sports and exercise: results from an illustrative survey